vericiguat

Details

Files
Generic Name:
vericiguat
Project Status:
Active
Therapeutic Area:
Heart failure
Manufacturer:
Bayer Inc.
Call for patient/clinician input open:
Brand Name:
Verquvo
Project Line:
Reimbursement Review
Project Number:
SR0758-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Bayer requests VERQUVO be reimbursed for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy. VERQUVO should be used in combination with standard of care therapy for heart failure. Initiation criteria: In adult patients with New York Heart Association (NYHA) II to IV chronic HF Other HF therapies include an angiotensin-converting enzyme inhibitor (ACEi), an angiotensin II receptor antagonist (ARB) or an angiotensin receptor and neprilysin inhibitor (ARNi), a beta-blocker, and if tolerated, a mineralocorticoid receptor antagonist (MRA) VERQUVO should be initiated under the supervision of a healthcare professional who is experienced in the management of HF.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
VERQUVO (vericiguat) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy. VERQUVO should be used in combination with standard of care therapy for heart failure.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openSeptember 15, 2022
Call for patient/clinician input closedNovember 04, 2022
Clarification:

- Patient input submission received from HeartLife Foundation and Heart function clinic Vancouver General Hospital, St Paul's Hospital

Submission receivedOctober 14, 2022
Submission acceptedOctober 28, 2022
Review initiatedOctober 31, 2022
Draft CADTH review report(s) provided to sponsor for commentJanuary 19, 2023
Deadline for sponsors commentsJanuary 31, 2023
CADTH review report(s) and responses to comments provided to sponsorMarch 09, 2023
Expert committee meeting (initial)March 22, 2023
Draft recommendation issued to sponsorMay 10, 2023
Draft recommendation posted for stakeholder feedbackMay 18, 2023
End of feedback periodJune 02, 2023